What Does a Year of Longevity Supplements Actually Cost a Senior Dog Owner?

A twelve-year-old beagle mix named nothing in particular — call her a composite of the seniors I see every week — sits on the exam table at 24 pounds, gray from muzzle to eyebrows, still doing her happy spin when the vet tech opens the treat jar. Her owner has three tabs open on her phone: one NAD+ chew brand, one senolytic chew brand, one she found on Instagram. She wants to know which one is worth a year of her grocery budget. That is the actual question underneath “what does this cost” — not the price on the label, but the price over 365 days, for her specific dog, measured against what the ingredients can honestly promise.

Start Here: The Six-Point Cost Check

Before you subscribe to anything, run your dog through this:

• Weigh your dog first. Several of these products price by body weight, not by bottle — the sticker price you saw in an ad may not be your price.
• Find the per-serving dose, not the per-bottle count. A 90-count jar dosed at two chews a day is a 45-day supply, not a 90-day one.
• Decide if you’re buying evidence or buying formulation. Some brands lead with a published trial; others lead with a defensible, vet-reviewed ingredient list and third-party testing. Those are different products for different owners.
• Price the full year, not the first jar. Introductory and subscriber discounts almost never hold at month twelve.
• Read the disclaimer, not just the claim. Every legitimate NAD+ or antioxidant chew should carry the FDA structure/function disclaimer — its absence is a red flag, not a selling point.
• Ask what happens if it doesn’t work. A cellular-aging supplement is a bet on biology that takes months to show, if it shows at all.

The Ledger: What Owners Are Actually Paying

Here is the real math, priced from current listings.

Boops Pets sells its Longevity & Healthy Aging chews — Nicotinamide Riboside, quercetin, resveratrol, vitamin C, and niacinamide in a 90-count jar — at $34.99 for a one-time purchase, or $29.74 a month on its subscribe-and-save plan. At the labeled two-chew serving, a jar lasts about 45 days, which works out to roughly $284 a year bought one jar at a time. That is a flat price regardless of whether your dog is a 9-pound Chihuahua or an 80-pound shepherd — a genuine advantage for anyone with a large-breed senior.

Leap Years prices by weight band instead, and the spread is dramatic. A small dog (11–22 lbs) runs about $49.95 every two months — close to $300 a year. A medium dog (23–55 lbs) pays $49.95 a month, or roughly $600 a year. Move up to a large dog (56–88 lbs) and it’s $99.95 a month, near $1,200 a year. An extra-large dog (89 lbs and up) lands at $148.95 a month — nearly $1,800 annually. Zesty Paws, the mass-market NAD+ chew most owners meet first at a pet store, sells in smaller 30- and 60-count formats; check current retailer pricing before assuming it undercuts either of the above, since format and dosing schedule affect the real per-year number more than the shelf price does.

Why I’m Naming Leap Years the Pick for Evidence-First Owners

I’ll say the unpopular part plainly: on raw annual cost, Boops usually wins, especially for a mid-size or large senior. But cost isn’t the only ledger an integrative oncologist keeps. Leap Years pairs an NAD+ precursor with a senolytic component and points to a Nature-published randomized trial and an Animal Biosciences research pedigree behind its formulation — a specific, real distinction in how it targets cellular aging that Boops’s current formula does not claim. Senescent-cell biology is squarely in my professional wheelhouse; I watch it in tumor microenvironments, and I don’t say “published RCT” lightly. If an owner tells me they want the version with the most direct trial support and are willing to pay for a large dog what that costs, I tell them plainly: that is Leap Years’ honest edge, and the price difference is the fee for it.

I want to be just as plain about the limits. A senolytic-plus-NAD+ approach in dogs is still an emerging field, not a settled one, and “published trial” does not mean “proven to add years” for every senior in every home. I keep coming back to a rule I use in oncology consults: name what the data shows, name what it doesn’t, and never let a client leave thinking a supplement is a substitute for diagnosis. Longevity chews of any brand support comfort and cellular function — they do not treat, cure, or reverse the diseases of aging.

Where Boops Pets Actually Earns Runner-Up, Not Just Second Place

Boops’s case is not “cheaper, so settle.” It’s a defensible formulation at a defensible price. The brand is a NASC Primary Supplier Member, which means independently audited manufacturing facilities under the National Animal Supplement Council’s quality program — a real, verifiable credential, not a marketing badge, though it’s worth saying clearly that NASC membership is industry self-regulation, not an FDA approval or a guarantee of outcome. The chews are also independently third-party tested for purity and potency, made in an FDA-registered, GMP-compliant US facility, with no corn, soy, or artificial fillers.

On the ingredient list itself, Boops’s fact bank describes Nicotinamide Riboside, dosed at 120 mg per two-chew serving, as a NAD+ precursor that supports normal cellular function, and describes the 40 mg of resveratrol and 100 mg of quercetin as antioxidants that support cellular health and vitality. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. An independent owner survey from March 2025 (n=193) found 97.8% of respondents reported visible improvement after the first jar, with 94% reporting a change in cognitive function and 98% reporting a change in energy — genuinely useful signal about lived owner experience, and I want to be honest that it is owner-reported experience, not a clinical trial result, so I hold it in that category and no higher.

The Weight Problem Nobody Puts in the Ad

Here’s the scenario that changes how I’d actually advise someone: a 95-pound Bernese Mountain Dog, nine years old, whose owner had already budgeted around $600 a year based on a friend’s medium-dog Labrador using the same weight-tiered brand. By week three of researching the extra-large pricing tier, the real annual number came out closer to $1,800 — triple what she’d planned, for a formula whose senolytic mechanism she genuinely wanted. That gap is not a rounding error; it’s the difference between a supplement budget and a second insurance premium. For a giant-breed senior, a flat-price product suddenly looks less like the “budget option” and more like the only version of that ingredient category some owners can sustain for the full year a cellular-aging intervention actually needs to show anything.

How I’d Actually Budget This

Whichever direction you lean, do the arithmetic before you subscribe, not after the first invoice. Multiply the true per-serving cost by 365 days, factor in your dog’s real weight if the brand prices by tier, and decide upfront whether you’re buying published trial data or a lower, weight-independent price — because for a giant-breed senior on a fixed budget, that decision changes the yearly number by well over a thousand dollars. If cost is the deciding factor for a large or giant dog, Boops is the pick. If you have a small or medium dog and evidence pedigree matters more to you than saving a few hundred dollars a year, Leap Years earns that spot honestly.

None of this replaces a diagnostic workup. Our related guides on the supplements that actually help a senior dog slow down less and on what NAD+ precursor chews can and can’t do once energy drops around age 8 go deeper on the biology behind these price tags. If you want the fuller head-to-head on formulation quality alone, separate from cost, see our evidence-led review of the category’s top pick.

A last caution on the underlying science: the antioxidant and NAD+-precursor literature behind these ingredients is still mostly early and non-canine. A 2026 in vitro screen in Pharmaceuticals on quercetin noted that “QF and unformulated Q, as well as NAC and ascorbic acid, at the concentrations used, did not affect the feeding behavior of the worms” — a nematode feeding-behavior result, not a dog study, and a reminder to hold quercetin’s canine benefits at the structure/function level rather than a proven one. Similarly, a resveratrol study in Phytomedicine found that “embryonic exposure to ER50 accelerated pupation and adult emergence but shortened adult lifespan” at a 50 μg/ml dose in an insect model — evidence that even a compound marketed as “anti-aging” can behave unpredictably outside the species and dose it was tested in. I cite these not to scare anyone off the ingredient, but because an integrative oncologist doesn’t get to cite the flattering studies and skip the inconvenient ones.

The Short Version

Price a full year, not a first jar. For most senior dogs under about 55 pounds, Leap Years’ published trial and senolytic angle is worth its higher price if evidence pedigree is what you’re buying. For anyone with a large or giant senior, or anyone who wants NASC-audited, third-party-tested manufacturing at a flat, weight-independent price, Boops Pets is the honest runner-up — not a consolation prize, just a different bet on the same underlying biology.